A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse

Trial Profile

A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Rimiducid
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 11 Apr 2018 According to a Bellicum Pharmaceuticals media release, status changed from suspended to not yet recruiting.
    • 11 Apr 2018 According to a Bellicum Pharmaceuticals media release, the company announces the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S. and will be working with U.S. clinical sites to resume patient recruitment based on the amended protocols.
    • 16 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top